Drugs / EPACMARSTOBART
EPACMARSTOBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04502706 | Nov 2020 → Mar 2022 | non-Hodgkin lymphoma | Gilead Sciences | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPACMARSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095341 ↗ |
| Known as | FSI-189 | “Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab” NCT04502706 ↗ |
| Known as | GS-0189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04502706 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095341 ↗ |
| Route | Intravenous | “GS-0189 will be administered intravenously.” NCT04502706 ↗ |